Knop, S. and Hebart, H. and Gscheidle, H. and Holler, Ernst and Kolb, H. J. and Niederwieser, D. and Einsele, H. (2005) OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. BONE MARROW TRANSPLANTATION, 36 (9). pp. 831-837. ISSN 0268-3369,
Full text not available from this repository. (Request a copy)Abstract
We retrospectively evaluated response to monoclonal antibody directed against CD3 (OKT3) treatment in 43 patients with steroid-resistant acute graft-versus-host disease (aGvHD) following allogeneic hematopoietic cell transplantation. Median duration of OKT3 therapy was 9 (range, 1-20) days. In all, 20 cycles were administered as second-line and 28 as third-plus line treatment. Side effects were mild to moderate. Overall response rate was 69 with 12% complete remissions and best response in skin involvement. Proportional reduction of concomitant steroids was higher in responding patients. Five patients (12%) achieved durable responses. Pharmacokinetic studies of OKT3 showed adequate plasma levels (>= 1000 ng/ml) in 13 of 17 evaluable patients after a median of 6 (1-11) days on treatment. OKT3 became undetectable shortly after discontinuation of therapy. Median survival for all patients was 80 (2 to 2474+) days. There was a trend for better survival for patients on second-line vs third-plus line treatment (146 vs 46 days; P = 0.07) and significant longer survival for patients with grade II when compared to those with grade III/IV aGvHD (206 vs 47 days; P = 0.039). We conclude that salvage treatment with OKT3 shows considerable efficiency, however, sometimes of transient nature, and is well tolerated in patients with corticosteroid-resistant aGvHD.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW-TRANSPLANTATION; ANTI-THYMOCYTE GLOBULIN; MONOCLONAL-ANTIBODIES; ACUTE GVHD; LYMPHOPROLIFERATIVE DISORDER; ANTITHYMOCYTE GLOBULIN; THERAPY; LYMPHOCYTES; DONORS; stem cell transplantation; graft-versus-host disease; monoclonal antibody; OKT3 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Apr 2021 09:40 |
| Last Modified: | 23 Apr 2021 09:40 |
| URI: | https://pred.uni-regensburg.de/id/eprint/35453 |
Actions (login required)
 |
View Item |
